Faes Farma SA
MAD:FAE
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
3.29
5.38
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| ES |
F
|
Faes Farma SA
MAD:FAE
|
1.6B EUR |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
969.6B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
547.3B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
277.1B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
209.4B GBP |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
219B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
271.3B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.7T DKK |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
148.3B USD |
Loading...
|
|
| FR |
|
Sanofi SA
PAR:SAN
|
93.8B EUR |
Loading...
|
Market Distribution
| Min | -9 204.1% |
| 30th Percentile | 1.8% |
| Median | 7.6% |
| 70th Percentile | 19% |
| Max | 603.4% |
Other Profitability Ratios
Faes Farma SA
Glance View
Faes Farma SA, a notable player in the pharmaceutical arena, has orchestrated its operations with the precision of a seasoned conductor. Rooted in Spain with an impressive international reach, the company blends research prowess with adept production capabilities. Central to its modus operandi is the development, manufacture, and commercialization of a wide range of pharmaceutical products and nutritional supplements. With science as its guiding star, Faes Farma dedicates substantial resources to research and development, ensuring a pipeline filled with innovative treatments that cater to diverse medical needs. The company has carved its niche by focusing on therapeutic areas such as allergy, dermatology, and the central nervous system, allowing it to create specialized solutions that resonate well with healthcare providers and patients alike. The company’s revenue engine is driven primarily by its robust product sales, enhanced by strategic partnerships and licensing agreements that bolster its market presence both in Spain and across global markets. Through rigorous production processes, Faes Farma ensures the delivery of high-quality medications, matching industry standards and fostering consumer trust. Additionally, its geographical diversification, with subsidiaries and distribution channels spreading across Europe, Latin America, and Africa, underpins its economic durability. By marrying innovation with strategic commercial tactics, Faes Farma has deftly navigated the complexities of the pharmaceutical landscape, ensuring not only profitability but also the sustained delivery of health-enhancing products to the global community.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Faes Farma SA is 18.5%, which is below its 3-year median of 20.4%.
Over the last 3 years, Faes Farma SA’s Net Margin has decreased from 19.6% to 18.5%. During this period, it reached a low of 18.5% on Sep 30, 2025 and a high of 22.6% on Dec 31, 2024.